Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibrin sealant patch - Takeda

Next Previous
Drug Profile

Fibrin sealant patch - Takeda

Alternative Names: Absorbable fibrin sealant patch; Fibrin-sealant; Medicated sponge - Nycomed; TachoComb; TachoSil

Latest Information Update: 24 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer Corza Health; Takeda Pharmaceuticals International GmbH
  • Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Fibrinogen replacements; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Surgical blood loss

Most Recent Events

  • 20 Apr 2023 Preregistration for Surgical blood loss (In children, In infants, In adolescents) in USA (Topical)
  • 20 Apr 2023 Fibrin sealant patch receives a positive Opinion from EMA for use in pediatric patients in Europe
  • 02 Feb 2021 Corza Health acquires assets and licenses for the development and commercialization of fibrin sealant patch (TachoSil®)from Takeda
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top